This interview with a US Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes, as well as pricing pressures within the diabetes market, the unmet needs in type 1 diabetes, and upcoming therapies in the pipeline. Key marketed and pipeline assets highlighted include Tresiba, Toujeo, and teplizumab.